In France, pharmaceutical giant Sanofi has entered into talks to sell a controlling 50% stake in its consumer health business Opella to a US private equity firm. The sale is estimated at around 15 billion euros. And the potential deal is already raising eyebrows. Opella employs more than 11,000 people and owns brands like the painkiller Doliprane, popular in its home market.
